Fluorodeoxyglucose whole-body positron emission tomography in colorectal cancer patients studied in routine daily practice

Abstract

A whole-body positron emission tomography scan provides optimum conditions to locate metastatic lesions that might not be seen otherwise. There is a trend showing that positron emission tomography diagnostics as a consequence of early increased tumor markers is a highly sensitive combination, because computed tomography and magnetic resonance imaging were not as sensitive in early recurrences. Positron emission tomography, as performed in daily clinical practice, proved to be a powerful diagnostic tool in our subset of colorectal cancer patients.

18F-FDG positron emission tomography staging and restaging in rectal cancer treated with preoperative chemoradiation

“…FDG-PET staging of locally advanced rectal cancer has a potential double function: staging both the systemic risk of dissemination and the locoregional disease extension (14). In the case of whole-body staging, the literature is abundant and consistent in other types of human cancer, particularly in non-small-cell lung cancer.…”

“…FDG-PET is the imaging technique of election to discriminate between the benign or malignant nature of presacral residual postsurgical masses in rectal cancer patients (10), although infection can lead to false positive findings. FDG-PET provides excellent metabolic information and permits staging Reprint search of metastatic disease and evaluation of treatment changes induced in the primary rectal cancer lesion (11). The standardized uptake value (SUV) is a measurement of the metabolic tissue activity used to discriminate between benign or malignant tissue, and is indirectly related to the aggressiveness of each individual cancer (12,13).…”

Utility of 2-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography in Managing Patients of Colorectal Cancer With Unexplained Carcinoembryonic Antigen Elevation at Different Levels

“…FDG-PET was useful in evaluating unexplained elevation of tumor markers during follow-up of colorectal cancer, thyroid cancer, cervical cancer, ovarian cancer, and breast cancer. [12][13][14][15][16][17][20][21][22][23] The results from our study and several other series for unexplained CEA eleva- tion in colorectal cancer are summarized in Table 4. The accuracy of FDG-PET ranges from 50 to 91 percent and the impact on clinical management ranges from 38 to 87 percent.…”

“…[12][13][14][15][16][17] To the best of our knowledge, the utility of FDG-PET combined with serum CEA level had not been systemically examined before. In this retrospective study we want to evaluate the utility of FDG-PET in colorectal cancer patients with unexplained CEA elevation at different CEA levels, and whether a higher CEA cutoff value for unexplained CEA elevation is justified to reduce the number of patients indicated for FDG-PET.…”

The Role of Positron Emission Tomography in the Management of Recurrent Colorectal Cancer: A Review

“…[24][25][26][28][29][30][31][32]34,37,40,63,64,76,80 When data are pooled, 37 percent of 914 patients_ management was influenced by the addition of PET to conventional imaging, a finding supported by a recent study. 81 PET has the greatest impact by detecting unresectable disease 31,33,64,77,80 and thereby averting inappropriate surgery.…”